Univ.Prof. Dr. Bob Djavan

Director minimal invasive and Prostate Center
Director Urology, Vienna Urology Foundation,Chairman regional office EAU
Rudolfinerhaus Foundation Hospital

Dr Alberto Bossi

Dr Alberto Bossi is currently Head of the Urology and Prostate Brachytherapy Unit at the Gustave Roussy Cancer Institute in Villejuif, France. His professional career started in Italy where he was born: he graduated in Medicine and Surgery in 1988 and specialized in Radiotherapy and Diagnostic Radiology in 1992 at the University of Pavia. After a Clinical Fellowship at the Dept of Radiation Oncology at the Academic Medical Centre in Amsterdam he worked in Como and Milan. In 2001 he was appointed Adjunct Clinical Head at the Department of Radiation Oncology of the University Hospital in Leuven, Belgium where he worked till 2006 before moving to IGR.

Dr Bossi is member of several scientific societies, including ESTRO, ASTRO, EAU. He has served as Coordinator of the Genito-Urinary Working Group of the EORTC in 2006. He is the Course Director of the Multidisciplinary ESTRO-EAU-ESMO Teaching Course on Prostate Cancer and teacher at both the ESO (European School of Oncology) and EAU (European Association of Urology) Prostate Courses. He is PI and co-PI (Principal Investigator) of two major European Phase III trials on Prostate Cancer and has published over 40 papers in peer-reviewed journals. Dr Bossi is reviewer for several journals including the IJROBP, European Urology, Radiotherapy and Oncology, Annals of Oncology.

Bouthaina S. Dabaja, M.D

Dr. Bouthaina Dabaja received her Medical Doctorate at the Lebanese University. She completed her clinical residencies at the American University of Beirut and The University of Texas MD Anderson Cancer Center. She began her career at MD Anderson following her residency in 2006 and has progressed from Assistant Professor to Professor and Section Chief of the Hematology Section in Radiation Oncology. Her primary clinical goal is patient care with an emphasis on maintaining and improving cure rate in patients with lymphoma while decreasing the short and long term side effects of treatment. She is extensively involved in clinical trials to investigate multiple strategies to deliver better treatment options for lymphoma patients with the goal of minimizing long term side effects on patients treated for mediastinal lymphomas which remains a great clinical challenge.

Professor Dirk Arnold

Associate Professor, Department of Radiation Oncology,

ESMO Board Member

Dirk Arnold is Director of the Dept. Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg and Berlin. His major field of scientific interest are gastrointestinal cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he serves as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in clinical oncology. Within the AIO framework, he served as founding member of the Central Clinical Trials Office, underlining his expertise also in methodology of clinical research. Furthermore, his interest is the organisation of larger collaborative research structures and of integrated cancer centre networks. Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group. Furthermore, he is board member of the German Society of Haematology and Medical Oncology (DGHO), and member of the German Cancer Society. Within ESMO, since 2012 he is section editor for GI cancers in the Guidelines Committee and Associate Editor with .

Dr.Stefan Rauh

Consultant of Clinical Radiotherapy and Assistant Professor

Centre Hospitalier Emile Mayrisch (CHEM) Luxembourg Dr Stefan Rauh works as a medical oncologist/haematologist at the Centre Hospitalier Emile Mayrisch (CHEM), Differdange and Esch in Luxembourg. Born 1964 in Munich, Germany, he studied Medicine in Munich and Lausanne, Switzerland, followed by post-graduate training in Munich, Nancy, France and Luxembourg. In 1999, he was given the opportunity to develop an oncology unit (including out-patient hospital and palliative unit) at Differdange Regional Hospital. In 2010 the hospital merged with Esch, making a total of 500 beds. He is now part of the CHEM oncology unit with palliative care and President of CHEM’s Plateform Cancer. His work is mainly clinical, however his work also includes teaching and clinical research activity and he is interested in co-operations with developing countries. At present, he serves as a tutor and lecturer at the General Medicine Faculty of the University of Luxembourg. He is currently involved in eight international clinical phase 3 and 4 studies, and has developed prospective randomised studies in out patient symptom monitoring in Luxembourg (pro-elects). Studies involve the CRP Santé, CIEC and IBBL, some are in collaboration with the CHL. Dr Rauh is Vice President of the Société Luxembourgeoise d’Oncology and a member of the National Tumor Registry’s board, the National Plan Cancer, the Luxembourg National Cancer Center Project and of the Scientific Council of the National Social Security. Dr Rauh is a qualified member of ESMO and served as the National Representative for Luxembourg for eight years. From 2015, he is the Chair of the ESMO Practising Oncologists Working Group and has a seat on the ESMO Executive Board. In addition, he is an extended member of the ESMO Public Policy Working Group. He is also a member of ASCO, ASH and a volunteer of Health Volunteers Overseas.  


تهران.هتل المپیک





عضویت در خبرنامه